{"url":"https://economictimes.indiatimes.com/tech/technology/boston-based-bicara-therapeutics-goes-public-lists-on-nasdaq/articleshow/113711740.cms","title":"With IPO, have the capital and resources for clinical studies: Bicara CEO","description":"​​As per Reuters, shares of Bicara Therapeutics surged nearly 46% in their debut on September 13, giving the TPG-backed cancer therapy developer a market value of $1.29 billion. Its shares opened at $26.25, compared with the offer price of $18, the news agency said. Bicara raised $315 million by selling 17.5 million shares in its initial public offering, after increasing the size of its offer twice, it said.","content":"Claire Mazumdar, chief executive of Boston-based Bicara Therapeutics, said the company has sufficient funds and resources to carry out clinical studies after its recent $315 million initial public offering (IPO). Claire is the niece of Biocon chief Kiran Mazumdar Shaw.","cleaned_content":"claire mazumdar chief executive of boston based bicara therapeutics said the company has sufficient funds and resources to carry out clinical studies after its recent \u003cTHREE_HUNDRED\u003e million initial public offering ipo claire is the niece of biocon chief kiran mazumdar shaw","timestamp":"2024-09-26T23:37:00+05:30","market_timestamp":"2024-09-27T09:15:00+05:30","off_market_hours":true}